NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has announced that a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP to initiate the trial and has appointed Professor Patrick Katoto as principal investigator. Preparatory work, including staff training, is underway, and the NV-387 drug product is already available in the DRC. First patient dosing is anticipated within a few weeks, barring any outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The company believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusions. This approach may simplify administration and improve patient compliance, which is critical in regions with limited healthcare infrastructure. The trial will be conducted with Om Sai Clinical Research Private Limited serving as the contract research organization (CRO), which will also support the company's planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC.
The initiation of this trial marks a pivotal step for NanoViricides in advancing its lead drug candidate, NV-387, into human clinical trials. The company has been focused on developing broad-spectrum antivirals that can address multiple viral threats, including Ebola, Mpox, and respiratory viruses such as RSV and COVID-19. The current Ebola outbreak in the DRC, caused by the Bundibugyo strain, underscores the urgent need for effective treatments. If successful, NV-387 could provide a much-needed therapeutic option that is easier to deploy in outbreak settings.
NanoViricides' technology is based on proprietary nanomedicine that aims to create targeted antiviral agents. The company holds a worldwide exclusive perpetual license to this technology for several viral diseases, including Ebola and Marburg viruses. The Phase II trial will evaluate the safety and efficacy of NV-387 in patients infected with Ebola, with the potential to expand its use to other viral infections. The company's broader pipeline includes candidates for COVID-19, influenza, and herpes, among others.
The move to oral gummies is particularly notable, as most existing antiviral treatments for Ebola are administered intravenously, requiring cold storage and trained medical personnel. An oral formulation could be distributed more easily and taken without specialized equipment, making it more feasible in remote areas. This aligns with global health efforts to improve outbreak response and reduce mortality rates.
NanoViricides' progress in the DRC follows its commitment to advancing NV-387 through clinical development. The company has emphasized that the path to drug approval is lengthy and requires substantial capital, and there are no guarantees of success. However, the initiation of this trial represents a meaningful step forward in addressing viral outbreaks with innovative treatment options.
For more information about NanoViricides and its programs, visit the company's newsroom at https://ibn.fm/NNVC.
